Tilray Brands Inc vs GeneDx Holdings Corp — how do they compare? Tilray Brands Inc trades at $3.47 (market cap $530.54M), while GeneDx Holdings Corp trades at $67.75 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 3.8× Tilray Brands Inc's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tilray Brands Inc for 31 Days and GeneDx Holdings Corp for 19 Days on average.
| TLRY | WGS | |
|---|---|---|
Market Cap | $530.54M | $2.02B |
Volume | 9,099,075 | 734,640 |
Sector | Health | Health |
52-Week High | $21.00 | $167.51 |
52-Week Low | $3.57 | $34.51 |
Typical Hold Time | 31 Days | 19 Days |
Enterprise Value | $684.46M | $2.05B |
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →